General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Key performance indicators

Novartis access-to-healthcare programs 2013

Research & Development FTEs1 Value (USD millions)2
Novartis Institute for Tropical Diseases
111
17.8
Novartis Vaccines Institute for Global Health
46
8.8
Novartis Institutes for BioMedical Research neglected disease programs
35
8.3
Total
192
34.9

Patient assistance

Patients reached (thousands)

Value (USD millions)3
Novartis Patient Assistance Foundation, Inc.
86.0
542.0
Glivec patient assistance4
55.0
1 108.1
Tasigna patient assistance4
4.1
107.8
Exjade patient assistance
6.8
26.8
Alcon medical missions5
518.1
62.2
Alcon US patient assistance
11.3
13.7
Malaria6
102 273.5
208.8
Leprosy (WHO)
243.6
4.5
Tuberculosis7
22.0
0.5
Fascioliasis/Egaten8
152.7
0.1
Emergency relief (medicine donations)
2.1
Total
103 373.1
2 076.6

Health systems strengthening

FTEs

People reached (thousands)9

Patients reached (thousands)

Value (USD millions)2
Novartis Foundation for Sustainable Development
7
3 613.8
9.9
Novartis research capacity-building programs
6
1
6.0
Social Business:10Healthy Family in India, Kenya and Vietnam
563
4 503.8
239.2
Total
576
8 118.6
239.2
15.9

Grand total

768

8.1 million

103.6 million

2.1 billion


  1. Full-time equivalent positions and contractors
  2. Operating costs
  3. Wholesale acquisition cost (WAC) plus logistic costs for some programs
  4. Value and patients include donations under shared contribution, co-pay models, and full donation
  5. Retail value for surgical products
  6. During 2013, 102.3 million Coartem treatments reached patients based on a preliminary analysis of local distribution. Of these, 58 million treatments came from shipments completed in 2012, and 44.3 million from shipments in 2013. A total of 72.8 million treatments were shipped in 2013. Value was calculated using the number of treatments shipped in 2013 and the ex-factory price of Coartem to private-sector purchasers in malaria-endemic developing countries, excluding private-sector buyers using the Affordable Medicines Facility for malaria and private-sector buyers using new channels to expand access.
  7. Last shipments of fixed-dose combination tablets to adult patients in Tanzania to complete TB drug donation
  8. Manufacturing cost
  9. Via training and service delivery
  10. People reached via training